Benjamin Besse: Should we infuse IO in the morning?

Benjamin Besse, Head of Clinical Research on Gustave Roussy, shared on X:

“Should we infuse IO in the morning? Intriguing work just published: Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy. .

We may need to analyze timing of IO infusion in phase III trials to guide us in our daily clinic.”

Read further.
Source: Benjamin Besse/X